US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX) ニュース

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SNDX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/16	07 : 34	PR Newswire (US)	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/13	21 : 00	PR Newswire (US)	Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/08	11 : 20	PR Newswire (US)	Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/07	21 : 00	PR Newswire (US)	Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2025/01/04	06 : 05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/21	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/09	21 : 30	PR Newswire (US)	Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/08	08 : 15	PR Newswire (US)	Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/07	06 : 28	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/12/04	06 : 05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/27	21 : 00	PR Newswire (US)	Syndax Announces Participation at the Citi 2024 Global Healthcare Conference	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/16	07 : 29	PR Newswire (US)	Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/12	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/12	21 : 00	PR Newswire (US)	Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/06	06 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/06	06 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/06	06 : 01	PR Newswire (US)	Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	23 : 01	PR Newswire (US)	Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	23 : 00	PR Newswire (US)	Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	23 : 00	PR Newswire (US)	Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/05	06 : 01	PR Newswire (US)	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/02	05 : 05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/11/01	20 : 00	PR Newswire (US)	Syndax Announces Participation in November Investor Conferences	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/10/29	20 : 00	PR Newswire (US)	Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/10/22	05 : 11	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/10/05	05 : 05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/09/19	06 : 15	PR Newswire (US)	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/09/07	05 : 05	PR Newswire (US)	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/08/16	05 : 15	Business Wire	Incyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc
2024/08/15	19 : 26	Business Wire	Incyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)	NASDAQ:SNDX	Syndax Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:SNDX

1 2 3 4 5 6 7 8 9 10 次へ >>

Bank of America

Energy Select Sector SPDR

Verizon Communications

Deutsche Telekom (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約